JPWO2021202642A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021202642A5 JPWO2021202642A5 JP2022559435A JP2022559435A JPWO2021202642A5 JP WO2021202642 A5 JPWO2021202642 A5 JP WO2021202642A5 JP 2022559435 A JP2022559435 A JP 2022559435A JP 2022559435 A JP2022559435 A JP 2022559435A JP WO2021202642 A5 JPWO2021202642 A5 JP WO2021202642A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- dose
- tumor
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003598P | 2020-04-01 | 2020-04-01 | |
| US63/003,598 | 2020-04-01 | ||
| PCT/US2021/025054 WO2021202642A2 (en) | 2020-04-01 | 2021-03-31 | Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023520392A JP2023520392A (ja) | 2023-05-17 |
| JPWO2021202642A5 true JPWO2021202642A5 (https=) | 2024-04-10 |
| JP2023520392A5 JP2023520392A5 (https=) | 2024-04-10 |
Family
ID=77929889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559435A Pending JP2023520392A (ja) | 2020-04-01 | 2021-03-31 | 間葉系幹細胞由来癌細胞および間葉系幹細胞関連疾患を標的とするイムノセラノスティック剤（ｉｍｍｕｎｏｔｈｅｒａｎｏｓｔｉｃ ａｇｅｎｔ） |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230133775A1 (https=) |
| EP (1) | EP4125991A4 (https=) |
| JP (1) | JP2023520392A (https=) |
| KR (1) | KR20220161395A (https=) |
| CN (1) | CN115379848A (https=) |
| AU (1) | AU2021246485A1 (https=) |
| BR (1) | BR112022019758A2 (https=) |
| CA (1) | CA3174263A1 (https=) |
| WO (1) | WO2021202642A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115975036B (zh) * | 2022-08-18 | 2023-06-09 | 北京诺赛国际医学研究院 | 包含干细胞的药物组合物及其治疗癌症的用途 |
| WO2024081729A2 (en) * | 2022-10-12 | 2024-04-18 | Mythic Therapeutics, Inc. | Lrrc-15-binding protein constructs and uses thereof |
| TW202434310A (zh) * | 2023-01-27 | 2024-09-01 | 日商第一三共股份有限公司 | 抗lrrc15抗體 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025160129A1 (en) * | 2024-01-23 | 2025-07-31 | The Regents Of The University Of California | Methods of use of agents targeting mesenchymal stem cell- derived tumors and tumor associated cells |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025264059A1 (ko) * | 2024-06-20 | 2025-12-26 | 주식회사 에디스바이오텍 | Lrrc15에 특이적으로 결합하는 항체 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9862770B2 (en) * | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| AR090549A1 (es) * | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| SG10201900002QA (en) * | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| JP2016056165A (ja) * | 2014-08-12 | 2016-04-21 | 学校法人藤田学園 | 抗α６β４インテグリン抗体を利用したがん又は腫瘍の診断又は治療のための抗体製剤及び抗体キット |
| AU2016365114A1 (en) * | 2015-11-30 | 2018-05-17 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| EP3383910A1 (en) * | 2015-11-30 | 2018-10-10 | AbbVie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
| US10221242B2 (en) * | 2016-01-21 | 2019-03-05 | Pfizer Inc. | Antibodies specific for epidermal growth factor receptor variant III and their uses |
| WO2018083087A2 (en) * | 2016-11-02 | 2018-05-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Binding proteins |
| EP3634485A4 (en) * | 2017-06-07 | 2021-07-21 | Silverback Therapeutics, Inc. | CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES |
| TWI823906B (zh) * | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
| US20210154188A1 (en) * | 2018-04-02 | 2021-05-27 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| CN112041337B (zh) * | 2018-04-16 | 2025-01-07 | 日本医事物理股份有限公司 | 修饰抗体、及放射性金属标记抗体 |
-
2021
- 2021-03-31 CA CA3174263A patent/CA3174263A1/en active Pending
- 2021-03-31 BR BR112022019758A patent/BR112022019758A2/pt unknown
- 2021-03-31 JP JP2022559435A patent/JP2023520392A/ja active Pending
- 2021-03-31 AU AU2021246485A patent/AU2021246485A1/en active Pending
- 2021-03-31 EP EP21780744.5A patent/EP4125991A4/en active Pending
- 2021-03-31 WO PCT/US2021/025054 patent/WO2021202642A2/en not_active Ceased
- 2021-03-31 KR KR1020227037264A patent/KR20220161395A/ko active Pending
- 2021-03-31 US US17/915,377 patent/US20230133775A1/en active Pending
- 2021-03-31 CN CN202180025582.7A patent/CN115379848A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7828375B2 (ja) | 標的分子に対する抗原結合コンストラクト | |
| US20240026027A1 (en) | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ | |
| IL261666B1 (en) | Binding proteins and methods of use thereof | |
| JP2019513018A5 (https=) | ||
| JP2012501648A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| RU2011112324A (ru) | Полиспецифические антитела | |
| JP2019205480A5 (https=) | ||
| RU2009137784A (ru) | Человеческое опухолеспецифическое моноклональное антитело | |
| JP2017531028A5 (https=) | ||
| JP2002515511A (ja) | 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 | |
| JPWO2021202642A5 (https=) | ||
| JP2021508707A5 (https=) | ||
| Luo et al. | Design and applications of bispecific heterodimers: molecular imaging and beyond | |
| JP2008529494A5 (https=) | ||
| JP2020534012A5 (https=) | ||
| EP4101472A1 (en) | Anti-meflin antibody for use in treatment cancer in subject having cancer, and pharmaceutical composition including said antibody | |
| JP2010514413A5 (https=) | ||
| JP2024020436A5 (https=) | ||
| RU2007104040A (ru) | Улучшенная вспомогательная терапия опухолей, экспрессирующих g250 | |
| US20250312468A1 (en) | Anti-protac antibodies and complexes | |
| WO2019087994A1 (ja) | 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤 | |
| Wong | Basic immunology of antibody targeted radiotherapy | |
| Scheuer et al. | 213 POSTER Enhanced antitumour effect by combination of HER2-targeting antibodies with bevacizumab in a human breast cancer xenograft model | |
| WO2024141496A1 (en) | Vhh anti-protac antibodies and complexes |